EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RCAS-1 serum and tumor levels in head and neck squamous cell carcinoma



RCAS-1 serum and tumor levels in head and neck squamous cell carcinoma



European Surgical Research. Europaische Chirurgische Forschung. Recherches Chirurgicales Europeennes 44(3-4): 214-219



RCAS-1 is a transmembrane protein that is involved in the evasion of host immune surveillance by tumor cells. It has been found to be a valuable prognostic and diagnostic marker in a number of different malignancies. The objective of the study was to analyze the potency of RCAS-1 as a biomarker in the serum of patients with head and neck squamous cell carcinoma (HNSCC). ELISA was performed with prospectively collected serum samples from 60 patients with HNSCC (taken at the time of diagnosis, after 3 and 12 months) and from 31 healthy controls. To correlate serum levels with RCAS-1 expression in the tumor, immunohistochemical staining of RCAS-1 was done using a tissue microarray. Surprisingly, median sRCAS-1 levels were basically identical between tumor patients and controls. Interestingly, patients with low RCAS-1 values at the time of diagnosis had better disease-free survival. 62% of tumor samples expressed RCAS-1 but we could not demonstrate a correlation between protein expression and serum levels. This study was the first to correlate RCAS-1 levels in the serum and in the tumor of the same patients. RCAS-1 seems to have prognostic properties although larger studies will be necessary to fully evaluate its role in HNSCC.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333731

Download citation: RISBibTeXText

PMID: 20571277

DOI: 10.1159/000314613



Related references

Serum levels of tumor necrosis factor in squamous cell carcinoma of the head and neck. American Journal of Otolaryngology 15(4): 281-285, 1994

Cathepsin B and L and stefin A and B levels as serum tumor markers in squamous cell carcinoma of the head and neck. Neoplasma 48(1): 66-71, 2001

Serum glycoproteins in head and neck squamous carcinoma: correlations with tumor extent, clinical tumor stage, and T-cell levels during chemotherapy. American Journal of Surgery 138(4): 489-500, 1979

Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells. Oncology Reports 27(4): 1135-1141, 2012

Lipid-associated sialic acid, squamous cell carcinoma antigen, carcinoembryonic antigen, and lactic dehydrogenase levels as tumor markers in squamous cell carcinoma of the head and neck. Cancer (philadelphia). 70(10): 2499-2503, 1992

Serum levels of interleukins 4 and 10 in head and neck squamous cell carcinoma. Journal of Laryngology and Otology 126(2): 175-179, 2012

The usefulness of new serum tumor markers in head and neck squamous cell carcinoma. Otolaryngology--Head and Neck Surgery 140(3): 375-380, 2009

Serum folate and homocysteine levels in head and neck squamous cell carcinoma. Cancer 95(10): 2252-3; Author Reply 2253-4, 2002

Serum ferritin as a tumor marker in patients with squamous cell carcinoma of the head and neck. Cancer 57(2): 305-311, 1986

Serum nitric oxide levels in patients with head and neck squamous cell carcinoma. Kulak Burun Bogaz Ihtisas Dergisi 17(3): 148-151, 2007

Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma. Anticancer Research 20(5a): 3045-3049, 2000

Early Detection of Serum Levels of HER-2 in Patients with Head and Neck Squamous Cell Carcinoma. Iranian Journal of Otorhinolaryngology 25(72): 161-168, 2013

Serum levels of intercellular adhesion molecule-1 in squamous cell carcinoma of the head and neck. Tumour Biology 18(2): 88-94, 1997

Elevated serum levels of malondialdehyde in patients with squamous cell carcinoma of the head and neck. Proceedings of the American Association for Cancer Research Annual Meeting 35(0): 94, 1994

Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Research 25(4): 2761-2765, 2005